Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Jinan Tantu Chemicals Letermovir

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Letermovir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 12,265Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AiCuris Achieves Milestones In Anti-viral Solutions For At-Risk Patients
    AiCuris Achieves Milestones In Anti-viral Solutions For At-Risk Patients

    17 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240711766000/en

    BUSINESSWIRE
    17 Jul 2024
    Share Share
    Health Canada approves new indication for Merck’s Prevymis
    Health Canada approves new indication for Merck’s Prevymis

    22 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168699&sid=2

    PHARMABIZ
    22 Apr 2024
    Share Share
    Merck Receives Positive EU CHMP Opinion for PREVYMIS
    Merck Receives Positive EU CHMP Opinion for PREVYMIS

    17 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231017269974/en

    BUSINESSWIRE
    17 Oct 2023
    Share Share
    Merck's CMV drug is approved for kidney transplant patients
    Merck's CMV drug is approved for kidney transplant patients

    07 Jun 2023

    // Katherine Lewin ENDPTS

    https://endpts.com/fda-updates-mercks-label-for-cytomegalovirus-drug-to-include-kidney-transplant-patients/

    Katherine Lewin ENDPTS
    07 Jun 2023
    Share Share
    U.S. FDA Approves New Indication for Merck’s PREVYMIS for Prevention of CMV
    U.S. FDA Approves New Indication for Merck’s PREVYMIS for Prevention of CMV

    06 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230606005563/en

    BUSINESSWIRE
    06 Jun 2023
    Share Share
    U.S. FDA Accepts for Priority Review the Supplemental NDA for Merck’s PREVYMIS
    U.S. FDA Accepts for Priority Review the Supplemental NDA for Merck’s PREVYMIS

    17 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230217005097/en

    BUSINESSWIRE
    17 Feb 2023
    Share Share